Brain tumors (primary and metastatic) after surgical and/or radiotherapeutic procedures. Hodgkin disease in combination with other chemotherapy agents after primary therapy has failed. Also used off-label in recurrent glioblastoma.
130 mg/m² orally as a single dose every 6 weeks. Dose adjustments required for hematologic toxicity. Administer on an empty stomach to reduce nausea.
Myelosuppression (nadir 4-6 weeks): Delayed, cumulative; requires 6-week dosing interval. Pulmonary Fibrosis: With cumulative doses. Secondary Malignancies. Hepatotoxicity. Embryo-Fetal Toxicity.
Thrombocytopenia (65%), leukopenia (65%), nausea/vomiting (45-50%), anorexia (common), alopecia (common)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
Lomustine (CCNU) alkylates and crosslinks DNA strands, inhibiting DNA synthesis and inducing cell death. As a lipophilic molecule, it crosses the blood-brain barrier effectively, making it particularly useful for CNS tumors. It also carbamoylates proteins via its isocyanate moiety.
Half-life: ~1-2 days (parent); active metabolites 16-48 hrs. Route: Oral. Refer to the full prescribing information for complete pharmacokinetic data.
Clinical efficacy and safety data are available in the full prescribing information and referenced publications.
Brain tumors (primary and metastatic) after surgical and/or radiotherapeutic procedures. Hodgkin disease in combination with other chemotherapy agents after primary therapy has failed. Also used off-label in recurrent glioblastoma.
Lomustine (CCNU) alkylates and crosslinks DNA strands, inhibiting DNA synthesis and inducing cell death. As a lipophilic molecule, it crosses the blood-brain barrier effectively, making it particularly useful for CNS tumors. It also carbamoylates proteins via its isocyanate moiety.
Thrombocytopenia (65%), leukopenia (65%), nausea/vomiting (45-50%), anorexia (common), alopecia (common)